INNOVATE Corp. Third Quarter 2026 Earnings Conference Call - INNOVATE CORP

Financial Performance:

• Consolidated revenue reached $495.5 million for Q3 2026, up 42.8% year-over-year (YoY) from $347.1 million, driven primarily by the Infrastructure segment.
• Net income attributable to common stockholders was $15.8 million ($1.10 per fully diluted share), a significant turnaround from a net loss of $9.4 million ($0.71 per share) in the prior year period.
• Adjusted EBITDA totaled $40.5 million, more than doubling from $19.8 million YoY; Infrastructure EBITDA rose to $43.6 million from $23.5 million, while Life Sciences and Spectrum EBITDA declined.
• Infrastructure segment revenue surged 45% to $490.6 million with adjusted EBITDA margin expanding 200 basis points to 8.9% (EBITDA of $43.6 million).
• Life Sciences revenue dropped 61.3% to $1.2 million due to lower unit sales at R2, though adjusted EBITDA loss improved due to reduced compensation expenses.
• Spectrum revenue fell to $3.7 million (from $5.6 million) reflecting only two months of consolidation prior to the sale of controlling interest; adjusted EBITDA was $0.3 million.
• Deferred revenue indicators show Infrastructure backlog at $2.7 billion (adjusted) with $500 million recognized from existing backlog; R2 entered Q4 with $1.9 million in future revenue recognized from 116 systems.
• Post-quarter debt was significantly reduced: total principal indebtedness stood at $238.3 million (down from $583.3 million pre-transaction), achieved by repaying $325 million in senior notes and the corporate credit line using $413 million in proceeds from the DBM Global sale.
• Cash and cash equivalents were $4.9 million as of September 30, 2026.

Guidance and Future Outlook:

• Management anticipates continued strong underlying demand for R2 technology and focuses on converting its backlog into revenue.
• MetaBeacon expects broader clinical adoption and reimbursement coding improvements, with initial transdermal GFR usage in Big Pharma clinical trials anticipated in 2027.
• R2 production capacity is scaling, with 30 systems delivered and 60 in production at Electronic Instrument and Technology (EIT), with deliveries scheduled by November 30, 2026.
• MetaBeacon plans to ship 600 units for China orders between Q4 2026 and Q2 2027.
• Future growth strategy involves monetizing remaining assets to further reduce debt and unlocking value through a focused portfolio on MetaBeacon and R2.
• Long-term goals include expanding R2's international presence and capitalizing on the potential for a second broadcast auction for the retained Spectrum stake.

Business Segments and Product Lines:

• Infrastructure (DBM Global): Completed sale of controlling interest to IES Holdings on October 5, 2026; delivered a record quarter with 170 basis points gross margin improvement; key activity areas include AI infrastructure, semiconductors, energy systems, and digital connectivity in NYC and healthcare.
• Life Sciences (MetaBeacon): Advanced commercialization of the TGFR system for kidney function assessment; nominated for the 2026 "Prick Scallion USA" Best Medical Technology Award; secured 600 monitor orders in China; FDA approved investigational device exemption for third-generation wireless TGFR sensor for validation studies.
• Life Sciences (R2): Worldwide demand reached 3.1 million units; recognized revenue of 1.2 million units; manufacturing ramp-up ongoing with EIT facility expansion.
• Spectrum: Completed sale of controlling interest to ConnexCorp in Q3; Innovate retains a 25% equity interest with an option to acquire up to 15% additional shares; owns 287 operating stations (largest Class A owner) and focuses on spectrum asset utility beyond linear broadcasting.
• Hidden/Off-Balance Sheet Assets: Holds a 75% economic interest in Pantsend (via its 76% stake in Benevir), eligible for up to $900 million in milestones ($500 million to Innovate); owns 80% of Genoval, a knee replacement device developer.

Market and Competitive Landscape:

• DBMG operates in a robust construction environment supported by sustained investment in computing, AI, advanced manufacturing, and energy systems.
• MetaBeacon faces a competitive but growing market for kidney function assessment, leveraging prestigious awards and expanding engagement with key opinion leaders and hospital value analysis committees.
• R2 benefits from strong global demand for its technology, necessitating rapid manufacturing scale-up to meet order volumes.
• Spectrum is positioned to capitalize on a second FCC broadcast auction and expanding opportunities for utility in spectrum assets beyond traditional broadcasting.
• Life sciences sector shows growing interest from Big Pharma in preclinical and clinical trials using transdermal GFR technology.

Risks and Challenges:

• Forward-looking statements carry risks regarding uncertainties in actual results differing materially from projections.
• Life Sciences revenue volatility due to the time-intensive nature of converting commercial pipelines into utilization (6-12 months).
• Dependency on regulatory approvals for MetaBeacon's new wireless sensor and reimbursement coding decisions from CMS and private payers.
• Execution risks regarding manufacturing ramp-up for R2 to meet 1.9 million units in pipeline and delivery timelines.
• Market concentration risks in infrastructure project timing and material cost fluctuations impacting margins in the maintenance business.

Management Commentary and Tone:

• Tone was highly confident and positive, emphasizing "exceptional performance," "significant progress," and "strong operating momentum."
• Management highlighted the strategic success of portfolio simplification, crediting the DBM Global sale with crystallizing value and providing substantial liquidity.
• Paul Voigt expressed pride in the DBMG team's accomplishments and framed the retained ownership stakes as opportunities for continued participation in success.
• CFO Mike Senna maintained a disciplined tone regarding capital allocation, highlighting the successful reduction of the balance sheet and debt load post-sale.

Analyst Questions and Answers:

• The transcript indicates a Q&A session was opened but explicitly states there were "no questions this afternoon."
• No specific analyst inquiries or management responses regarding guidance, margins, or segment details are recorded in the provided text.

Other Key Points:

• The call included a disclaimer regarding forward-looking statements and the use of non-GAAP measures (Adjusted EBITDA) with reconciliations available in the earnings release.
• The sale of DBM Global to IES Holdings is identified as a major milestone for simplifying the corporate structure.
• Innovate retains a 25% stake in Spectrum with an option to increase to 40%, signaling ongoing interest in the media/broadcasting sector.
• The "Prick Scallion" award nomination for MetaBeacon's TGFR system is highlighted as a validation of the technology's innovation.
• Debt reduction efforts were accelerated by the DBM Global transaction proceeds, reducing total principal indebtedness by over $340 million post-quarter.